Onconetix Faces Nasdaq Delisting Notice Amid Compliance Issues

An update from Onconetix ( (ONCO) ) is now available.

On May 16, 2025, Onconetix, Inc. issued a promissory note to Keystone Capital Partners, LLC, with an original issue discount of $44,117.65, in a principal amount of $294,117.65, due upon certain conditions or by February 16, 2026. The note is subordinate to existing debt obligations and incurs a late charge if unpaid when due. On May 20, 2025, Onconetix received a deficiency notice from Nasdaq for failing to file its Quarterly Report on Form 10-Q for the period ended March 31, 2025, which could lead to delisting. The company had previously received similar notices for failing to file its Annual Report on Form 10-K and not maintaining the minimum bid price for its stock. A hearing is scheduled for May 27, 2025, and the company is working to file the necessary reports to regain compliance.

Spark’s Take on ONCO Stock

According to Spark, TipRanks’ AI Analyst, ONCO is a Underperform.

Onconetix’s overall score reflects substantial financial difficulties with significant operating losses and negative profitability metrics. The technical analysis suggests a bearish trend, and the valuation metrics are unfavorable due to negative earnings. These factors combine to give the stock a low attractiveness score.

To see Spark’s full report on ONCO stock, click here.

More about Onconetix

Onconetix is a commercial stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s health and oncology. The company owns Proclarix®, an in vitro diagnostic test for prostate cancer approved for sale in the EU, and ENTADFI, an FDA-approved pill for treating benign prostatic hyperplasia.

Average Trading Volume: 22,005,915

Technical Sentiment Signal: Sell

Current Market Cap: $3.9M

For a thorough assessment of ONCO stock, go to TipRanks’ Stock Analysis page.